Janelle Nicole Ruiz1, Viswanath Reddy Belum2, Patricia Creel3, Allen Cohn4, Michael Ewer5, Mario E Lacouture6. 1. Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY; Stanford School of Medicine, Stanford, CA. 2. Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY. 3. Duke Cancer Institute, Duke University Medical Center, Durham, NC. 4. Rocky Mountain Cancer Centers, Denver, CO. 5. MD Anderson Cancer Center, Houston, TX. 6. Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: lacoutum@mskcc.org.
Abstract
BACKGROUND: Oncologists treating patients with targeted therapies encounter adverse events (AEs) that pose management challenges, lead to dosing inconsistencies, and impact patient quality of life. Oncologists' practices and attitudes in the management of targeted therapy-related AEs in patients with renal cell carcinoma (RCC) are poorly understood. We sought to identify unmet needs associated with AE management and understand oncologists' treatment optimization strategies. METHODS: A 24-item online survey was administered in August 2012 to 119 US oncologists treating patients with advanced RCC. The survey solicited responses regarding demographics, practice settings, AE management practice patterns and beliefs, treatment barriers, and patient education. RESULTS: Respondents indicated that between 25% and 50% of patients require dose modification/discontinuation because of AEs. The greatest barrier to optimizing treatment for RCC is the unpredictability of patient responses to treatment (43%). Most respondents (78%) discuss AE management with patients, but only a minority of them proactively reach out to patients (46%). Most practitioners (70%) refer patients to nononcology specialists when faced with unfamiliar AEs, although finding interested physicians (43%) and time constraints (40%) were the most commonly cited barriers to consulting with other specialties. CONCLUSION: Results suggest that many patients require dose modification/discontinuation because of AEs and that nononcologists are a frequently utilized resource to manage these events. There is a need for predictive drug toxicity markers to establish counseling and prevention, along with opportunities for increased education on supportive care techniques to maintain health-related quality of life and consistent dosing.
BACKGROUND: Oncologists treating patients with targeted therapies encounter adverse events (AEs) that pose management challenges, lead to dosing inconsistencies, and impact patient quality of life. Oncologists' practices and attitudes in the management of targeted therapy-related AEs in patients with renal cell carcinoma (RCC) are poorly understood. We sought to identify unmet needs associated with AE management and understand oncologists' treatment optimization strategies. METHODS: A 24-item online survey was administered in August 2012 to 119 US oncologists treating patients with advanced RCC. The survey solicited responses regarding demographics, practice settings, AE management practice patterns and beliefs, treatment barriers, and patient education. RESULTS: Respondents indicated that between 25% and 50% of patients require dose modification/discontinuation because of AEs. The greatest barrier to optimizing treatment for RCC is the unpredictability of patient responses to treatment (43%). Most respondents (78%) discuss AE management with patients, but only a minority of them proactively reach out to patients (46%). Most practitioners (70%) refer patients to nononcology specialists when faced with unfamiliar AEs, although finding interested physicians (43%) and time constraints (40%) were the most commonly cited barriers to consulting with other specialties. CONCLUSION: Results suggest that many patients require dose modification/discontinuation because of AEs and that nononcologists are a frequently utilized resource to manage these events. There is a need for predictive drug toxicity markers to establish counseling and prevention, along with opportunities for increased education on supportive care techniques to maintain health-related quality of life and consistent dosing.
Authors: Alyx C Rosen; Emily C Case; Stephen W Dusza; Yevgeniy Balagula; Jennifer Gordon; Dennis P West; Mario E Lacouture Journal: Am J Clin Dermatol Date: 2013-08 Impact factor: 7.403
Authors: Tim Eisen; Cora N Sternberg; Caroline Robert; Peter Mulders; Lynda Pyle; Stephan Zbinden; Hassan Izzedine; Bernard Escudier Journal: J Natl Cancer Inst Date: 2012-01-10 Impact factor: 13.506
Authors: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Roberto Pili; Georg A Bjarnason; Xavier Garcia-del-Muro; Jeffrey A Sosman; Ewa Solska; George Wilding; John A Thompson; Sindy T Kim; Isan Chen; Xin Huang; Robert A Figlin Journal: J Clin Oncol Date: 2009-06-01 Impact factor: 44.544
Authors: Brian I Rini; Darrel P Cohen; Dongrui R Lu; Isan Chen; Subramanian Hariharan; Martin E Gore; Robert A Figlin; Michael S Baum; Robert J Motzer Journal: J Natl Cancer Inst Date: 2011-04-28 Impact factor: 13.506
Authors: Sumanta K Pal; Bradley McGregor; Cristina Suárez; Che-Kai Tsao; William Kelly; Ulka Vaishampayan; Lance Pagliaro; Benjamin L Maughan; Yohann Loriot; Daniel Castellano; Sandy Srinivas; Rana R McKay; Robert Dreicer; Thomas Hutson; Sarita Dubey; Scott Werneke; Ashok Panneerselvam; Dominic Curran; Christian Scheffold; Toni K Choueiri; Neeraj Agarwal Journal: J Clin Oncol Date: 2021-09-07 Impact factor: 44.544
Authors: Alexander S Bang; Milan J Anadkat; Jennifer N Choi; Nicole R LeBoeuf; Jae Y Jung; Alina Markova; Allison Gordon; Anthony M Rossi; Sarah J Noor; Vincent Sibaud; Mario E Lacouture Journal: Am J Clin Dermatol Date: 2022-07-05 Impact factor: 6.233